Regulation of the HER3/ErbB3 Pseudokinase Domain by an ATP-Competitive Inhibitor

被引：0
|
作者：
Littlefield, Peter [1 ]
Moasser, Mark M. [1 ]
Jura, Natalia [1 ]
机构：
[1] Univ Calif San Francisco, San Francisco, CA 94143 USA
来源：
BIOPHYSICAL JOURNAL | 2014年 / 106卷 / 02期
关键词：
D O I：
10.1016/j.bpj.2013.11.2919
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：523A / 523A
页数：1
相关论文
共 50 条
  • [21] ERBB3/HER3 and ERBB2/HER2 Duet in Mammary Development and Breast Cancer
    David F. Stern
    Journal of Mammary Gland Biology and Neoplasia, 2008, 13
  • [22] Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase
    Garrett, Joan T.
    Olivares, Maria Graciela
    Rinehart, Cammie
    Granja-Ingram, Nara D.
    Sanchez, Violeta
    Chakrabarty, Anindita
    Dave, Bhuvanesh
    Cook, Rebecca S.
    Pao, William
    McKinely, Eliot
    Manning, H. C.
    Chang, Jenny
    Arteaga, Carlos L.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (12) : 5021 - 5026
  • [23] Pyrogallin, an ATP-Competitive Inhibitor of JAK3
    Lee, Byung Il
    Ahn, Hyung Jun
    Han, Ki-Cheol
    Ahn, Dae-Ro
    Shin, Dongyun
    BULLETIN OF THE KOREAN CHEMICAL SOCIETY, 2011, 32 (03): : 1077 - 1079
  • [24] Clinical efficacy of HER3 partners' inhibitors in ERBB3 mutated cancer patients
    Verlingue, L.
    Massard, C.
    Hollebecque, A.
    Alvarez, E. Castanon
    Postel-Vinay, S.
    Angevin, E.
    Armand, J-P.
    Aspeslagh, S.
    Varga, A.
    Ratislav, B.
    Gazzah, A.
    Michot, J-M.
    Lacroix, L.
    De Baere, T.
    Marabelle, A.
    Soria, J-C.
    ANNALS OF ONCOLOGY, 2016, 27
  • [25] ErbB3/HER3 does not homodimerize upon neuregulin binding at the cell surface
    Berger, MB
    Mendrola, JM
    Lemmon, MA
    FEBS LETTERS, 2004, 569 (1-3): : 332 - 336
  • [26] Clinical impact of HER3/ERBB3 expression in primary and recurrent ovarian cancer
    Yokosu, Kota
    Harano, Kenichi
    Yamashita, Riu
    Fujii, Satoshi
    Tanabe, Hiroshi
    Mukohara, Toru
    Sato, Saori
    Kobayashi, Maki
    Oshima, Keiko
    Kimura, Hiroko
    Takahashi, Hiroyuki
    Saito, Motoaki
    Yamada, Kyosuke
    Takano, Hirokuni
    Okamoto, Aikou
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A290 - A290
  • [27] ErbB3/HER3和erbB4/HER4在肺癌中的表达
    王治民
    陈少茂
    邓在春
    现代实用医学, 2003, (01) : 12 - 14
  • [28] A multiscale modeling approach to investigate molecular mechanisms of pseudokinase activation and drug resistance in the HER3/ErbB3 receptor tyrosine kinase signaling network
    Telesco, Shannon E.
    Shih, Andrew J.
    Jia, Fei
    Radhakrishnan, Ravi
    MOLECULAR BIOSYSTEMS, 2011, 7 (06) : 2066 - 2080
  • [29] Trans-activating mutations of the pseudokinase ERBB3
    Koivu, Marika K. A.
    Chakroborty, Deepankar
    Airenne, Tomi T.
    Johnson, Mark S.
    Kurppa, Kari J.
    Elenius, Klaus
    ONCOGENE, 2024, 43 (29) : 2253 - 2265
  • [30] ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells
    Choi, Byung-Kwon
    Fan, Xuejun
    Deng, Hui
    Zhang, Ningyan
    An, Zhiqiang
    CANCER MEDICINE, 2012, 1 (01): : 28 - 38
12345